Why the study?
Pediatric device-based therapy is limited by a lack of large clinical studies, leaving indications unclear, while somatic growth and low body weight introduce distinct technical challenges.
Answers are grounded in this paper and cite their sources.
Device therapy is a promising tool to reduce sudden cardiac death in children with congenital heart disease, but its implementation is limited by the lack of large clinical studies and technical challenges related to somatic growth and small body weight.
Sudden cardiac death in children is one of the most devastating conditions that can be encountered in acute cardiac care. Intracardiac device therapy, providing prompt and effective treatment in malignant ventricular arrhythmia or in severe conduction abnormalities, is a promising tool to reduce the incidence of this fatal condition. However, the implementation of device-based therapy in the pediatric population is currently limited by the lack of clinical studies on large number of subjects. As a result, indications for device therapy in pediatric patients are still unclear in many circumstances. There are also several particularities related to device implantation in pediatric age, such as the somatic growth leading to a mismatch between chamber size and lead length, or the difficulties of implantation technique in children with small body weight. This study aims to present an update on the current advantages and limitations of device-based therapy for treating severe malignant arrhythmia or conduction disorders in children at risk for sudden cardiac death.
No takes yet. Share an insight, caveat, or question.
Aura-Gabriela Casu (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: